OKYO Pharma’s (OKYO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

OKYO Pharma Price Performance

Shares of OKYO opened at $1.09 on Tuesday. OKYO Pharma has a 1-year low of $0.81 and a 1-year high of $1.90. The firm has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $1.07.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.